All Outputs (10)

A Quantitative Method for the Study of HIV-1 and Mycobacterium tuberculosis Coinfection (2022)
Journal Article
Donnellan, S., Pennington, S. H., Ruggiero, A., Martinez-Rodriguez, C., Pouget, M., Thomas, J., …Paxton, W. A. (2023). A Quantitative Method for the Study of HIV-1 and Mycobacterium tuberculosis Coinfection. Journal of Infectious Diseases, 227(5), 708-713. https://doi.org/10.1093/infdis/jiac491

Mycobacterium tuberculosis and human immunodeficiency virus-1 (HIV-1) syndemic interactions are a major global health concern. Despite the clinical significance of coinfection, our understanding of the cellular pathophysiology and the therapeutic pha... Read More about A Quantitative Method for the Study of HIV-1 and Mycobacterium tuberculosis Coinfection.

Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2 (2022)
Journal Article
Jeffreys, L. N., Pennington, S. H., Duggan, J., Caygill, C. H., Lopeman, R. C., Breen, A. F., …Biagini, G. A. (2022). Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. International Journal of Antimicrobial Agents, 59(3), Article 106542. https://doi.org/10.1016/j.ijantimicag.2022.106542

A key element for the prevention and management of COVID-19 is the development of effective therapeutics. Drug combination strategies of repurposed drugs offer several advantages over monotherapies, including the potential to achieve greater efficacy... Read More about Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.

Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi) (2021)
Book Chapter
Donnellan, S., Martínez-Rodríguez, C., Aljayyoussi, G., & Biagini, G. A. (2021). Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi). In C. Barreiro, & J. Barredo (Eds.), Antimicrobial Therapies: Methods and Protocols (393-408). New York: Humana Press. https://doi.org/10.1007/978-1-0716-1358-0

The human disease tuberculosis (TB) is the leading cause of death from a single infectious agent. A quarter of the world’s population is estimated to be latently infected. Drug development and screening is slow and costly. We have developed a physiol... Read More about Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi).

Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis (2019)
Journal Article
Donnellan, S., Aljayyoussi, G., Moyo, E., Ardrey, A., Martinez-Rodriguez, C., Ward, S. A., & Biagini, G. A. (2020). Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis. Antimicrobial Agents and Chemotherapy, 64(1), https://doi.org/10.1128/aac.00989-19

Clinical studies of new antitubercular drugs are costly and time-consuming. Owing to the extensive tuberculosis (TB) treatment periods, the ability to identify drug candidates based on their predicted clinical efficacy is vital to accelerate the pipe... Read More about Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis.

Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis (2019)
Journal Article
Donnellan, S., & Giardiello, M. (2019). Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis. Journal of Interdisciplinary Nanomedicine, 4(3), 76-85. https://doi.org/10.1002/jin2.61

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), causes the most human deaths than any other diseases from a single infectious agent. Treatments are long and costly and have many associated side effects. Intracellular bacilli are slow g... Read More about Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis.

Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing (2019)
Journal Article
Aljayyoussi, G., Donnellan, S., Ward, S. A., & Biagini, G. A. (2019). Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing. Pharmaceutics, 11(6), Article 278. https://doi.org/10.3390/pharmaceutics11060278

Increasing rifampicin (RIF) dosages could significantly reduce tuberculosis (TB) treatment durations. Understanding the pharmacokinetic-pharmacodynamics (PK–PD) of increasing RIF dosages could inform clinical regimen selection. We used intracellular... Read More about Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing.

Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity (2017)
Journal Article
Donnellan, S., Stone, V., Johnston, H., Giardiello, M., Owen, A., Rannard, S., …Stevenson, K. (2017). Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity. Journal of Interdisciplinary Nanomedicine, 2(3), 146-156. https://doi.org/10.1002/jin2.27

Tuberculosis kills more people worldwide than any other infectious disease. Treatment requires multiple drug therapy administered over long periods (6–24 months). The emergence of multidrug‐resistant strains is a major problem, and with few new drugs... Read More about Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity.

Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration (2017)
Journal Article
Aljayyoussi, G., Jenkins, V. A., Sharma, R., Ardrey, A., Donnellan, S., Ward, S. A., & Biagini, G. A. (2017). Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Scientific Reports, 7(1), Article 502 (2017). https://doi.org/10.1038/s41598-017-00529-6

Tuberculosis (TB) treatment is long and complex, typically involving a combination of drugs taken for 6 months. Improved drug regimens to shorten and simplify treatment are urgently required, however a major challenge to TB drug development is the la... Read More about Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration.

A rapid screening assay for identifying mycobacteria targeted nanoparticle antibiotics (2016)
Journal Article
Donnellan, S., Tran, L., Johnston, H., McLuckie, J., Stevenson, K., & Stone, V. (2016). A rapid screening assay for identifying mycobacteria targeted nanoparticle antibiotics. Nanotoxicology, 10(6), 761-769. https://doi.org/10.3109/17435390.2015.1124468

Antibiotic resistance is a serious problem. Nanotechnology offers enormous potential in medicine, yet there is limited knowledge regarding the toxicity of nanoparticles (NP) for mycobacterial species that cause serious human diseases (e.g. tuberculos... Read More about A rapid screening assay for identifying mycobacteria targeted nanoparticle antibiotics.

Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
Working Paper
Jeffreys, L., Pennington, S. H., Duggan, J., Breen, A., Jinks, J., Ardrey, A., …Biagini, G. A. (2020). Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

A key element to the prevention and management of the COVID-19 pandemic is the development of effective therapeutics. Drug combination strategies of repurposed drugs offer a number of advantages to monotherapies including the potential to achieve gre... Read More about Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2.